Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma

Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective tre...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2021-12, Vol.11, p.603591
Main Authors: Zhang, Jie Qing, Zhao, Bing Bing, Wang, Mao Mao, Li, Li
Format: Article
Language:English
Subjects:
case report
gynecologic oncology
maintenance therapy
niraparib
Oncology
ovarian carcinosarcoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c429t-d3a25b924c2973727bd1365beea00f71b533d4135d633d9e51a846175b707ce73
cites cdi_FETCH-LOGICAL-c429t-d3a25b924c2973727bd1365beea00f71b533d4135d633d9e51a846175b707ce73
container_end_page
container_issue
container_start_page 603591
container_title Frontiers in oncology
container_volume 11
creator Zhang, Jie Qing
Zhao, Bing Bing
Wang, Mao Mao
Li, Li
description Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.
doi_str_mv 10.3389/fonc.2021.603591
format article
fullrecord <record><control><sourceid>pubmed_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2cf1f22444954d3b9b09f8efce47b2fa</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2cf1f22444954d3b9b09f8efce47b2fa</doaj_id><sourcerecordid>34938651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-d3a25b924c2973727bd1365beea00f71b533d4135d633d9e51a846175b707ce73</originalsourceid><addsrcrecordid>eNpVkV1PXCEQholpo8Z675XhD-wKDBwOvWhiNrWa2No09uOODBxwMbuw4Zya-O9l3dYoNzNheJ8JeQg54WwO0JuzWLKfCyb4vGOgDN8jh0KAnBkJf9696g_I8Tjes3Y6xTiDfXIA0kDfKX5Ifi1wDPRH2JQ6faTfUsUN1uQojvQrpjyFjNkHersMbfJIU6bn9DtOKeSJ_k7Tkt48tPeY6QKrT7mMrZQ1fiDvI67GcPyvHpGfF59vF5ez65svV4vz65mXwkyzAVAoZ4T0wmjQQruBQ6dcCMhY1NwpgEFyUEPXGhMUx152XCunmfZBwxG52nGHgvd2U9Ma66MtmOzzRal3FuuU_CpY4SOPQkgpjZIDOOOYiX2IPkjtRMTG-rRjbf66dRh8-2LF1Rvo20lOS3tXHmzf9Upw3gBsB_C1jGMN8SXLmd0qs1tldqvM7pS1yOnrnS-B_4LgCdMMkwg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma</title><source>Open Access: PubMed Central</source><creator>Zhang, Jie Qing ; Zhao, Bing Bing ; Wang, Mao Mao ; Li, Li</creator><creatorcontrib>Zhang, Jie Qing ; Zhao, Bing Bing ; Wang, Mao Mao ; Li, Li</creatorcontrib><description>Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2021.603591</identifier><identifier>PMID: 34938651</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>case report ; gynecologic oncology ; maintenance therapy ; niraparib ; Oncology ; ovarian carcinosarcoma</subject><ispartof>Frontiers in oncology, 2021-12, Vol.11, p.603591</ispartof><rights>Copyright © 2021 Zhang, Zhao, Wang and Li.</rights><rights>Copyright © 2021 Zhang, Zhao, Wang and Li 2021 Zhang, Zhao, Wang and Li</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-d3a25b924c2973727bd1365beea00f71b533d4135d633d9e51a846175b707ce73</citedby><cites>FETCH-LOGICAL-c429t-d3a25b924c2973727bd1365beea00f71b533d4135d633d9e51a846175b707ce73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685211/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685211/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34938651$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Jie Qing</creatorcontrib><creatorcontrib>Zhao, Bing Bing</creatorcontrib><creatorcontrib>Wang, Mao Mao</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><title>Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.</description><subject>case report</subject><subject>gynecologic oncology</subject><subject>maintenance therapy</subject><subject>niraparib</subject><subject>Oncology</subject><subject>ovarian carcinosarcoma</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkV1PXCEQholpo8Z675XhD-wKDBwOvWhiNrWa2No09uOODBxwMbuw4Zya-O9l3dYoNzNheJ8JeQg54WwO0JuzWLKfCyb4vGOgDN8jh0KAnBkJf9696g_I8Tjes3Y6xTiDfXIA0kDfKX5Ifi1wDPRH2JQ6faTfUsUN1uQojvQrpjyFjNkHersMbfJIU6bn9DtOKeSJ_k7Tkt48tPeY6QKrT7mMrZQ1fiDvI67GcPyvHpGfF59vF5ez65svV4vz65mXwkyzAVAoZ4T0wmjQQruBQ6dcCMhY1NwpgEFyUEPXGhMUx152XCunmfZBwxG52nGHgvd2U9Ma66MtmOzzRal3FuuU_CpY4SOPQkgpjZIDOOOYiX2IPkjtRMTG-rRjbf66dRh8-2LF1Rvo20lOS3tXHmzf9Upw3gBsB_C1jGMN8SXLmd0qs1tldqvM7pS1yOnrnS-B_4LgCdMMkwg</recordid><startdate>20211206</startdate><enddate>20211206</enddate><creator>Zhang, Jie Qing</creator><creator>Zhao, Bing Bing</creator><creator>Wang, Mao Mao</creator><creator>Li, Li</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211206</creationdate><title>Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma</title><author>Zhang, Jie Qing ; Zhao, Bing Bing ; Wang, Mao Mao ; Li, Li</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-d3a25b924c2973727bd1365beea00f71b533d4135d633d9e51a846175b707ce73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>case report</topic><topic>gynecologic oncology</topic><topic>maintenance therapy</topic><topic>niraparib</topic><topic>Oncology</topic><topic>ovarian carcinosarcoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jie Qing</creatorcontrib><creatorcontrib>Zhao, Bing Bing</creatorcontrib><creatorcontrib>Wang, Mao Mao</creatorcontrib><creatorcontrib>Li, Li</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jie Qing</au><au>Zhao, Bing Bing</au><au>Wang, Mao Mao</au><au>Li, Li</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2021-12-06</date><risdate>2021</risdate><volume>11</volume><spage>603591</spage><pages>603591-</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>34938651</pmid><doi>10.3389/fonc.2021.603591</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2234-943X
ispartof Frontiers in oncology, 2021-12, Vol.11, p.603591
issn 2234-943X
2234-943X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_2cf1f22444954d3b9b09f8efce47b2fa
source Open Access: PubMed Central
subjects case report
gynecologic oncology
maintenance therapy
niraparib
Oncology
ovarian carcinosarcoma
title Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A36%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Case%20Report:%20Niraparib%20as%20Maintenance%20Therapy%20in%20A%20Patient%20With%20Ovarian%20Carcinosarcoma&rft.jtitle=Frontiers%20in%20oncology&rft.au=Zhang,%20Jie%20Qing&rft.date=2021-12-06&rft.volume=11&rft.spage=603591&rft.pages=603591-&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2021.603591&rft_dat=%3Cpubmed_doaj_%3E34938651%3C/pubmed_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-d3a25b924c2973727bd1365beea00f71b533d4135d633d9e51a846175b707ce73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/34938651&rfr_iscdi=true